Glucose Absorption and Gut Hormone Secretion After Gastric Bypass

Study Overview
=================
Brief Summary
-----------------
To investigate the impact of canagliflozin on secretion of gut hormones, in particular glucagon-like peptide 1 (GLP-1) in gastric bypass operated patients.

Detailed Description
-----------------
Glucose is a potent stimulus for GLP-1 secretion after gastric bypass surgery and the SGLT-1 transporter appears to be crucial for this response. The study will investigate the effects of SGLT-1/SGLT-2 inhibition (by canagliflozin) on secretion of GLP-1 and other gut hormones after gastric bypass surgery.

Official Title
-----------------
Impact of Canaglifloxin on Gut Hormone Secretion After Gastric Bypass

Conditions
-----------------
Overweight

Intervention / Treatment
-----------------
* Dietary Supplement: Glucose
* Dietary Supplement: Glucose + Canagliflozin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: •Uncomplicated gastric bypass surgery performed minimum 12 months prior to study Exclusion Criteria: Type 1 or 2 diabetes mellitus prior to or after gastric bypass surgery Pregnancy or breastfeeding Haemoglobin levels below 6,5 mM

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Interventional Model Description: 10 gastric bypass patients
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Glucose<br> | Dietary Supplement: Glucose<br>* Ingestion of glucose (50 g) dissolved in 200 ml water.<br>|
| Experimental: Glucose + Canagliflozin<br> | Dietary Supplement: Glucose + Canagliflozin<br>* Ingestion of glucose (50 g) dissolved in 200 ml water combined with the SGLT-1/SGLT-2 inhibitor canagliflozin.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in GLP-1 secretion (evaluated by iAUC). | Comparison of the GLP-1 responses (evaluated by iAUC) between the two test days. | 0-240 min following glucose ingestion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in glucose responses between the two test days. |  | 0-240 min following glucose ingestion | 
| Difference in insulin responses between the two test days. |  | 0-240 min following glucose ingestion | 
| Difference in C-peptide responses between the two test days. |  | 0-240 min following glucose ingestion | 
| Difference in Gastric Inhibitory Peptide (GIP) responses (evaluated by iAUC) between the two test days. |  | 0-240 min following glucose ingestion | 
| Difference in peptide YY (PYY) responses (evaluated by iAUC) between the two test days. |  | 0-240 min following carbohydrate ingestion | 
| Difference in glucagon responses (evaluated by iAUC) between the two test days. |  | 0-240 min following glucose ingestion | 
| Difference in oxyntomodulin responses (evaluated by iAUC) between the two test days. |  | 0-240 min following carbohydrate ingestion | 
| Difference in cholecystokinin (CCK) responses (evaluated by iAUC) between the two test days. |  | 0-240 min following glucose ingestion | 
| Difference in bile acid responses (evaluated by iAUC) between the two test days. |  | 0-240 min following glucose ingestion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glucagon-like Peptide-1, Glucose, Gastric bypass, Bariatric surgery, Obesity, Diabetes